{"id":588445,"date":"2026-09-21T00:00:00","date_gmt":"2026-09-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0002-2026-biopharma-major-depressive-disorder-dsm-v-landscape-forecast-disease-landscape-forecast-major\/"},"modified":"2026-09-21T00:00:00","modified_gmt":"2026-09-21T00:00:00","slug":"dlsfcg0002-2026-biopharma-major-depressive-disorder-dsm-v-landscape-forecast-disease-landscape-forecast-major","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0002-2026-biopharma-major-depressive-disorder-dsm-v-landscape-forecast-disease-landscape-forecast-major\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (Major Markets)"},"content":{"rendered":"<p>The major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) therapy market is crowded and highly genericized. Extensive use of generic agents\u2014particularly selective serotonin reuptake inhibitors (<abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s) as earlyline treatments\u2014creates substantial barriers for new branded therapies. Brandonly products (e.g., Lundbeck\/Takeda\u2019s Trintellix\/Brintellix; Lundbeck\/Otsuka Pharmaceutical\u2019s Rexulti\/Rxulti; AbbVie\u2019s Vraylar\/Reagila; Axsome\u2019s Auvelity; Johnson &#038; Johnson Innovative Medicine\u2019s Caplyta) primarily compete for use in treatmentrefractory patients. Johnson &#038; Johnson Innovative Medicine\u2019s Spravato offers a faster onset of therapeutic effect than currently approved therapies, addressing an important unmet need; however, its use in treatmentresistant depression remains limited by several constraints. Given the persistent unmet needs in <abbr title=\"major depressive disorder\">MDD<\/abbr>, physicians continue to look to emerging therapies\u2014many of which feature novel mechanisms of action\u2014as promising future options.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the current size of the <abbr title=\"major depressive disorder\">MDD<\/abbr> therapy market in the major markets, and which key events will influence the market over the next decade?<\/li>\n<li>What is the epidemiology of <abbr title=\"major depressive disorder\">MDD<\/abbr> in the major markets? What percentage of prevalent patients are diagnosed and drug-treated?<\/li>\n<li>What factors drive and constrain the use of branded antidepressants and atypical antipsychotics in <abbr title=\"major depressive disorder\">MDD<\/abbr>? Which branded therapy is expected to experience the most commercial success during the forecast period?<\/li>\n<li>What are the greatest areas of unmet need in the treatment of <abbr title=\"major depressive disorder\">MDD<\/abbr>, and how are emerging therapies expected to address these unmet needs?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geography: <\/strong>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan.<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading psychiatrists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Prevalence of <abbr title=\"major depressive disorder\">MDD<\/abbr> by country; diagnosed \/ drug-treated prevalence of <abbr title=\"major depressive disorder\">MDD<\/abbr> by country.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr title=\"major depressive disorder\">MDD<\/abbr> therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-588445","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/588445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=588445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}